The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-22. Anything still debated is marked as such rather than presented as settled.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
=== Psychedelics === Jung's theories are considered to be a useful therapeutic framework for the analysis of unconscious phenomena that become manifest in the acute psychedelic state. This view is based on correspondence Jung had with researchers involved in psychedelic research in the 1950s, as well as more recent neuroimaging research where subjects who are administered psychedelic compounds seem to have archetypal religious experiences of "unity" and "ego dissolution" associated with reduced activity in the default mode network. This research has led to a re-evaluation of Jung's work, particularly the visions detailed in The Red Book, in the context of contemporary psychedelic, evolutionary, and developmental neuroscience. For example, in a chapter entitled "Integrating the Archaic and the Modern: The Red Book, Visual Cognitive Modalities and the Neuroscience of Altered States of Consciousness", in the 2020 volume Jung's Red Book for Our Time: Searching for Soul Under Postmodern Conditions, Volume 4, it is argued Jung was a pioneer who explored uncharted "cognitive domains" that are alien to Western modes of thought. While such domains of experience are not part of mainstream Western culture and thought, they are central to various Indigenous cultures that use psychedelics such as Iboga and Ayahuasca during rituals to alter consciousness. The author writes: "Jung seems to have been dealing with modes of consciousness alien to mainstream Western thought, exploring the terrain of uncharted cognitive domains.
Derek, Davis (2007). "Rail Cars, Ice Cream, & Eggs". Penn Engineering Magazine. School of Engineering and Applied Science. Archived from the original on 2010-06-27. Retrieved 2010-10-25. Alt URL Heggie, Barbara (1941-09-06). "Ice Woman". New Yorker: 23. Retrieved 2010-10-25. Mary Engle Pennington at Find a Grave Pennington’s hearing on cold storage in front of the U.S. Congress House Committee on Agriculture, on August 19, 1919 Profile at National Women's Hall of Fame
==== International ==== DET is listed under Schedule I of the United Nations 1971 Convention on Psychotropic Substances, placing it under international control. This means that countries that are parties to the Convention are required to regulate DET production, distribution, and use, restricting it to scientific and very limited medical purposes. Possession and trade of DET without appropriate authorization is prohibited under international law.
Sources: en.wikipedia.org
Glycoproteins have differential levels of glycosylations and adsorb SDS more unevenly at the glycosylations, resulting in broader and blurred bands. Membrane proteins, because of their transmembrane domain, are often composed of the more hydrophobic amino acids, have lower solubility in aqueous solutions, tend to bind lipids, and tend to precipitate in aqueous solutions due to hydrophobic effects when sufficient amounts of detergent are not present. This precipitation manifests itself for membrane proteins in a SDS-PAGE in "tailing" above the band of the transmembrane protein. In this case, more SDS can be used (by using more or more concentrated sample buffer) and the amount of protein in the sample application can be reduced. An overloading of the gel with a soluble protein creates a semicircular band of this protein (e. g. in the marker lane of the image at 66 kDa), allowing other proteins with similar molecular weights to be covered. A low contrast (as in the marker lane of the image) between bands within a lane indicates either the presence of many proteins (low purity) or, if using purified proteins and a low contrast occurs only below one band, it indicates a proteolytic degradation of the protein, which first causes degradation bands, and after further degradation produces a homogeneous color ("smear") below a band. The documentation of the banding pattern is usually done by photographing or scanning. For a subsequent recovery of the molecules in individual bands, a gel extraction can be performed.
Shortly before his retirement in 1983, he submitted data requested by the FDA, which had begun to regulate medical devices following a 1977 meeting on the topic, regarding DBS for chronic pain. Medtronic and Neuromed also made deep brain stimulators at the time, but reportedly felt a complex safety and efficacy clinical trial in patients who were difficult to evaluate would be too costly for the size of the potential patient base, so did not submit clinical data on DBS for chronic pain to the FDA, and that indication was de-approved. However, near this time in France and elsewhere, DBS was investigated as a substitute for lesioning of brain nuclei to control motor symptoms of movement disorders such as Parkinson's disease, and by the mid-1990s, this reversible, non-destructive stimulation therapy had become the primary application of DBS in appropriate patients, to slow progression of movement impairment from the disease and reduce side effects from long-term, escalating medication use.
The Normans (Norman: Normaunds; French: Normands; Latin: Nortmanni/Normanni) were a population arising in the medieval Duchy of Normandy from the intermingling between Norse Viking settlers and locals of West Francia. The Norse settlements in West Francia followed a series of raids on the French northern coast mainly from what is now Denmark, although some also sailed from Norway and Sweden. These settlements were finally legitimized when Rollo, a Scandinavian Viking leader, agreed to swear fealty to King Charles III of West Francia following the siege of Chartres in 911, leading to the formation of the County of Rouen. This new fief, through kinship in the decades to come, would expand into what came to be known as the Duchy of Normandy. The Norse settlers, whom the region as well as its inhabitants were named after, adopted the language, religion, social customs and martial doctrine of the West Franks but their offspring nonetheless retained many of their traits, notably their mercenary tendencies and their fervour for adventures. The intermixing between Norse folk and native West Franks in Normandy produced an ethnic and cultural "Norman" identity in the first half of the 10th century, an identity which continued to evolve over the centuries. The Norman dynasty had a major political, cultural and military impact on medieval Europe and the Near East. The Normans were historically famed for their martial spirit, and eventually for their Catholic piety as adherents of the Catholic orthodoxy of the Romance community.
Though some studies indeed find this correlation, the consistent correlation between ophthalmic acid increases and glutathione depletion does not exist. Compared to a healthy baseline, both can go up, both can go down, or ophthalmic acid can go up with no changes in glutathione. A study on circadian rhythm tracking both glutathione and ophthalmic acid levels determined that ophthalmic acid levels were rhythmic, while glutathione levels were not. Ophthalmic acid trends also differ wildly between different tissues in the same animal at the same timepoint, again dispelling the notion of a broader and consistent correlation. The meaning of "biomarker" is much more narrow in this context than many studies assume. Importantly, the Soga et al. study sees a correlation between depleting hepatic glutathione levels, and rising ophthalmic acid levels in plasma, in mice. It solves the practical problem of not being able to directly measure an established glutathione depletion in liver by measuring ophthalmic acid in plasma. However, subsequent studies often measure both glutathione and ophthalmic acid, and when glutathione shows no aberration, ophthalmic acid is used as a "marker" to still claim oxidative stress. There cannot be an appeal to a correlation when the data itself disproves that very correlation. Ophthalmic acid can be found in high concentrations in healthy tissues. For instance in the eye. It is not solely found in stressed or diseased states.
Sources: en.wikipedia.org
Tang Chinese soldiers and pirates enslaved Koreans, Turks, Persians, Indonesians, and people from Inner Mongolia, central Asia, and northern India. The greatest source of slaves came from southern tribes, including Thais and aboriginals from the southern provinces of Fujian, Guangdong, Guangxi, and Guizhou. Malays, Khmers, Indians, and "black skinned" peoples (who were either Austronesian Negritos of Southeast Asia and the Pacific Islands, or Africans, or both) were also purchased as slaves in the Tang dynasty. In the 17th century Qing dynasty, there was a hereditarily servile people called Booi Aha (Manchu: booi niyalma; Chinese transliteration: 包衣阿哈), which is a Manchu word literally translated as "household person" and sometimes rendered as "nucai." The Manchu was establishing close personal and paternalist relationship between masters and their slaves, as Nurhachi said, "The Master should love the slaves and eat the same food as him". However, booi aha "did not correspond exactly to the Chinese category of "bond-servant slave" (Chinese:奴僕); instead, it was a relationship of personal dependency on a master which in theory guaranteed close personal relationships and equal treatment, even though many western scholars would directly translate "booi" as "bond-servant" (some of the "booi" even had their own servant). Chinese Muslim (Tungans) Sufis who were charged with practicing xiejiao (heterodox religion), were punished by exile to Xinjiang and being sold as a slave to other Muslims, such as the Sufi begs.
== Competitiveness == The Global Competitiveness Report 2019 published by the World Economic Forum, ranked 141 nations for national competitiveness, defined as the set of institutions, policies and factors that determine productivity. Thailand ranked 40 of 141 (1=best). Other ASEAN nations ranked were: Singapore, 1; Malaysia, 27; Indonesia, 50; Brunei, 56; Philippines, 64; Vietnam, 67; Cambodia, 106; Laos, 113. IMD World Competitive Rankings 2019: Ranked Thailand 25 of 63 nations (1=most competitive). Other ASEAN nations were ranked: Singapore, 1; Malaysia, 22; Indonesia, 32; Philippines, 46. Global Competitiveness Index (GCI) 2014-2015: Thailand ranked 32 of 140 economies in the World Economic Forum's GCI. It was ranked sixth in ASEAN+3 (China, Japan, South Korea). ASEAN partners Singapore ranked second and Malaysia 18th. IMD World Competitiveness Yearbook 2016: Thailand rose two places from 2015's ranking to rank 28 of 61 nations (1=best, 61=worst) in competitiveness. IMD World Competitiveness Yearbook 2015: Thailand ranked 30 of 61 nations. The ranking looks at 20 areas grouped around four main topics: economic performance, government efficiency, business efficiency, and infrastructure. Thailand's ranking in health and environment is its lowest, 54th. The best ranking is in the employment area (3rd) thanks low unemployment. Among 61 economies, Thailand's business legislation is also ranked poorly, at 51. In education, it is ranked 48.
Other processes are also used to purify water, including reverse osmosis, carbon filtration, microporous filtration, ultrafiltration, ultraviolet oxidation, or electrodialysis. These are used in place of, or in addition to, the processes listed above. Processes rendering water potable but not necessarily closer to being pure H2O / hydroxide + hydronium ions include the use of dilute sodium hypochlorite, ozone, mixed-oxidants (electro-catalyzed H2O + NaCl), and iodine; See discussion regarding potable water treatments under "Health effects" below.
Sigma RBI produces specialized products for use in the field of cell signaling and neuroscience. Their offerings range from standard biochemical reagents to specialized research tools, including ligands for receptors and ion channels, enzyme inhibitors, phosphospecific antibodies, key signal transduction enzymes, and assay kits for cell signaling.
== Overdose == Acute overdosage is often manifested by vomiting, lethargy, ataxia, tachycardia, and seizures. Plasma, serum, or blood concentrations of paroxetine may be measured to monitor therapeutic administration, confirm a diagnosis of poisoning in hospitalized patients or to aid in the medicolegal investigation of fatalities. Plasma paroxetine concentrations are generally in a range of 40–400 μg/L in persons receiving daily therapeutic doses and 200–2,000 μg/L in poisoned patients. Postmortem blood levels have ranged from 1–4 mg/L in acute lethal overdose situations. Along with the other SSRIs, sertraline and fluoxetine, paroxetine is considered a low-risk drug in cases of overdose.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.